GlassScriptPhysician profile
Raymond H Plack
NPI 1255325270
$2,631.48
in general payments reported to CMS, 2019-2025
29 companies · $233 in 2025
The $233 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $957 · 2020: $75.88 · 2021: $201 · 2022: $380 · 2023: $363 · 2024: $421 · 2025: $233.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,017.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,017.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $511.93 | 2019-2025 | |
| Medtronic, INC. | $400.07 | 2021-2025 | Azure Xt Dr Mri Surescan, Micra, Linq II |
| Amgen INC. | $246.94 | 2019-2025 | Repatha, Repatha |
| Astrazeneca Pharmaceuticals LP | $196.49 | 2019-2024 | Farxiga |
| Medtronic Vascular, INC. | $140.97 | 2019 | |
| Janssen Pharmaceuticals, INC | $138.23 | 2019-2024 | Xarelto |
| Abiomed | $127.96 | 2022 | |
| Shockwave Medical, INC | $123.63 | 2023 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.26 | 2020-2024 | Jardiance |
| Esperion Therapeutics, INC. | $86.61 | 2020-2025 | Nexletol |
| Gilead Sciences, INC. | $65.85 | 2019 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $53.58 | 2019 | |
| Chiesi USA, INC. | $50.62 | 2021-2023 | Kengreal |
| Regeneron Healthcare Solutions, INC. | $47.01 | 2019 | |
| Biosense Webster, INC. | $38.79 | 2025 | Carto 3 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Scpharmaceuticals INC. | $34.97 | 2025 | |
| Amarin Pharma, INC. | $34.10 | 2019-2022 | |
| E.R. Squibb & Sons, L.L.C. | $32.80 | 2019-2025 | Camzyos |
| Pfizer INC. | $28.15 | 2019 | |
| Cook Medical LLC | $26.10 | 2022 | |
| Irhythm Technologies, INC. | $24.38 | 2024 | Zio Monitor, Zio Xt Patch |
| Novo Nordisk INC | $20.00 | 2024 | Wegovy |
| Actelion Pharmaceuticals US, INC. | $17.33 | 2023 | Opsumit, Uptravi |
| Merck Sharp & Dohme LLC | $16.66 | 2023 | Verquvo |
| Teleflex LLC | $15.98 | 2019 | |
| Astellas Pharma US INC | $15.02 | 2019 | |
| Sanofi-Aventis U.S. LLC | $13.84 | 2019 | |
| Abbott Laboratories | $13.11 | 2019 | |
| Arbor Pharmaceuticals, INC. | $12.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raymond Plack listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.